Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07126678 | Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma | recruiting | N/A | 15 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05565807 | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 15, 2025 |
| clinicaltrials |
| NCT05913804 | YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 97 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06978088 | LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | recruiting | Phase 2 | 34 | Zulfa OmerOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05583071 | Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL(MTR²) | recruiting | Phase 2 | 20 | University of CologneOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06530550 | PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas | recruiting | Phase 2 | 51 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02393157 | Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL(O-ICE) | recruiting | Phase 2 | 25 | New York Medical CollegeOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT04099966 | AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion | recruiting | Phase 2 | 20 | Mitchell CairoOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07111884 | GMMG Multiple Myeloma Registry | recruiting | — | 999 | Prof. Dr. Hartmut GoldschmidtOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT06343311 | T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)(STARLIGHT-1) | recruiting | Phase 1 / Phase 2 | 21 | Estrella Biopharma, Inc.INDUSTRY | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06213636 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).(BAH241) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06365060 | Screening for AL Amyloidosis in Smoldering Multiple Myeloma | recruiting | — | 400 | Tufts Medical CenterOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106671 | A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106684 | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia(CAREMM-004) | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106710 | ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma(CAREMM-005) | recruiting | Phase 2 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106723 | Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106736 | MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma(MAGIC-TIEMM) | recruiting | Phase 2 | 60 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05841550 | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06793449 | BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma(CAREMM-006) | recruiting | Phase 2 | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06880393 | BCMA CAR-T for Dynamic High-risk Multiple Myeloma(CAREMM-003) | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06762769 | Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma(MODIFY) | recruiting | Phase 2 | 63 | University College, LondonOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT04961515 | Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma | recruiting | Phase 2 | 19 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05659732 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | recruiting | Phase 1 | 32 | PharmaEngineINDUSTRY | 2 | Jul 31, 2025 | clinicaltrials |
| NCT06838832 | Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | recruiting | Phase 1 / Phase 2 | 84 | Cancer Research UKOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07087964 | Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Diagnosed Multiple Myeloma Patients(IMMPROVED) | recruiting | — | 120 | Universiteit AntwerpenOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07085559 | Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | recruiting | Early Phase 1 | 36 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05841914 | Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma(DecodeVRL) | recruiting | — | 220 | Vinodh Kakkassery, MDOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06651853 | Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL | recruiting | Phase 2 | 22 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07079423 | Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis | recruiting | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06464991 | A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)(FUMANBA-03) | recruiting | Phase 3 | 240 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07074470 | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL(VPX) | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07072169 | A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) | recruiting | Phase 1 | 56 | Ruijin HospitalOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072208 | Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL | recruiting | N/A | 43 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072221 | Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients | recruiting | N/A | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04704323 | CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 18 | Catapult TherapeuticsINDUSTRY | 2 | Jul 17, 2025 | clinicaltrials |
| NCT07070648 | Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET | recruiting | — | 300 | Fudan UniversityOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07051850 | Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies | recruiting | — | 174 | Sung-Soo ParkOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03807128 | MYeloma Resistance And Clonal Evolution(MYRACLE) | recruiting | — | 1,400 | Nantes University HospitalOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT06682130 | Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL(ASCT DLBCL) | recruiting | Phase 2 | 40 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07059741 | Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL | recruiting | N/A | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT06976437 | A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors | recruiting | Early Phase 1 | 21 | YANRU WANGOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT06871176 | PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05618041 | The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies | recruiting | N/A | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07028970 | Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection | recruiting | — | 1,500 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2025source: clinicaltrials